Announcements Trials
Browse Landscape

Phase

Phase 2 7Phase 1/2 4Phase 1 3Phase 3 2

Status

Unknown 1Recruiting 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Plasma cell 2

Conditions

Multiple Myeloma 29Recurrence 7Neoplasms, Plasma Cell 2Bone Marrow Neoplasms 1

Interventions

Dexamethasone 20Melphalan 13Thalidomide 10Bortezomib 10Lenalidomide 8Cyclophosphamide 8Prednisone 6Filgrastim 6Doxorubicin 6Vincristine 5Epoetin Alfa 5pomalidomide 3Zoledronic Acid 3Peripheral Blood Stem Cell Transplantation 3Idarubicin 3carfilzomib 2Vorinostat 2Radiotherapy 2Interferon-alpha 2Granulocyte Colony-Stimulating Factor 2Early Intervention, Educational 2Darbepoetin alfa 2Carmustine 2Calcium Dobesilate 2Busulfan 2valspodar 1sargramostim 1oblimersen 1liposomal doxorubicin 1isatuximab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 3 × Neoplasms, Plasma Cell × carfilzomib × Clear all
NCT06152575 2026-06-05

MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide)

Pfizer

Phase 3 Recruiting
492 enrolled
Plasma cell

Multiple Myeloma, Neoplasms, Plasma Cell

NCT01554852 2018-06-11

Myeloma XI

University of Leeds

Phase 3 Unknown
4,420 enrolled
Plasma cell

Multiple Myeloma, Neoplasms, Plasma Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡